MarketLens
Sign Up

What Makes Roche's $700 Million Bet on Nurix So Significant

4 months ago
SHARE THIS ON:

What Makes Roche's $700 Million Bet on Nurix So Significant

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

Novartis agreed to license Abogen's lead autoimmune drug in a deal worth up to $7.8B, as Abogen claims the therapy could transform treatment for autoimmune diseases.
Stock News•3 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.
Stock News•3 months ago

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics secured a global collaboration with Roche for bexobrutideg, receiving a $700 million upfront payment with potential total payments up to $2.3 billion.

Breaking News

View All →

Top Headlines

View More →
Stock News•53 minutes ago

Amazon cloud capacity sold out through 2027, CEO Jassy says

Stock News•1 hour ago

GE Vernova (GEV) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•2 hours ago

Hottest toy for Christmas? Nvidia CEO plays with adorable Microduck robots, 20,000 sell

Stock News•2 hours ago

Turmoil hits AI buildout as neoclouds face pressure, credit risks mount and Solidigm pulls IPO

Stock News•3 hours ago

Kaplan Fox Notifies Investors of Alphabet Inc. (GOOGL, GOOG) of the Lead Plaintiff Deadline on December 1, 2026